Search results for "METASTASIS"

showing 10 items of 986 documents

Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis

2017

AbstractThe extranodal extension (ENE) of nodal metastasis involves the extension of neoplastic cells through the lymph node capsule into the perinodal adipose tissue. This morphological feature has recently been indicated as an important prognostic factor in various cancer types, but its role in prostate cancer is still unclear. We aimed to clarify it, performing the first meta-analysis on this issue, comparing prognostic parameters in surgically treated, node-positive prostate cancer patients with (ENE+) vs. without (ENE−) ENE. Data were summarized using risk ratios (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95% confidence intervals (CI), for the time-dependent r…

Male0301 basic medicineBiochemical recurrenceOncologymedicine.medical_specialtyPathologyScienceprostate cancer he extranodal extension (ENE) perinodal adipose tissuenot knownArticle03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineJournal ArticleOdds RatioHumansMedicineperinodal adipose tissueNeoplasms Adipose TissueAgedProportional Hazards ModelsMultidisciplinarybusiness.industryProportional hazards modelQHazard ratioRProstateProstatic NeoplasmsCancerOdds ratioMiddle Agedprostate cancerPrognosismedicine.disease3. Good health030104 developmental biologyLymphatic Metastasis030220 oncology & carcinogenesisRelative riskhe extranodal extension (ENE)MedicineProstate surgeryLymph NodesNeoplasm Recurrence LocalbusinessScientific Reports
researchProduct

Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma

2019

Background Vitronectin is a multifunctional glycoprotein known in several human tumors for its adhesive role in processes such as cell growth, angiogenesis and metastasis. In this study, we examined vitronectin expression in neuroblastoma to investigate whether this molecule takes part in cell-cell or cell-extracellular matrix interactions that may confer mechanical properties to promote tumor aggressiveness. Methods We used immunohistochemistry and image analysis tools to characterize vitronectin expression and to test its prognostic value in 91 neuroblastoma patients. To better understand the effect of vitronectin, we studied its in vitro expression using commercial neuroblastoma cell lin…

Male0301 basic medicineCancer ResearchAngiogenesislcsh:RC254-282MetastasisExtracellular matrixMice03 medical and health sciencesNeuroblastoma0302 clinical medicineCell Line TumorNeuroblastomaImage Interpretation Computer-AssistedTumor MicroenvironmentGeneticsmedicineAnimalsHumansDigital pathologyVitronectinMigrationTumor microenvironmentbiologyCell growthChemistryExtracellular matrixlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosismedicine.diseaseSurvival AnalysisUp-RegulationGene Expression Regulation Neoplastic030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchbiology.proteinImmunohistochemistryFemaleVitronectinNeoplasm TransplantationResearch Article
researchProduct

Infiltrating mast cell-mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotype

2019

Abstract Tumor growth and development is determined by both cancer cell–autonomous and microenvironmental mechanisms, including the contribution of infiltrating immune cells. Because the role of mast cells (MC) in this process is poorly characterized and even controversial, we investigated their part in breast cancer. Crossing C57BL/6 MMTV-PyMT mice, which spontaneously develop mammary carcinomas, with MC-deficient C57BL/6-KitW-sh/W-sh (Wsh) mice, showed that MCs promote tumor growth and prevent the development of basal CK5-positive areas in favor of a luminal gene program. When cocultured with breast cancer cells in vitro, MCs hindered activation of cMET, a master regulator of the basal pr…

Male0301 basic medicineCancer ResearchReceptor ErbB-2Estrogen receptorBreast NeoplasmsMice TransgenicCell CommunicationCell Growth ProcessesMice03 medical and health sciences0302 clinical medicineBreast cancerImmune systemCell Line TumormedicineAnimalsHumansMast CellsNeoplasm Metastasisskin and connective tissue diseasesEstrogen receptor activityMice Inbred BALB Cbusiness.industryMammary Neoplasms ExperimentalCancerProto-Oncogene Proteins c-metmedicine.diseaseMast cellPhenotypeErbB ReceptorsMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureReceptors EstrogenOncology030220 oncology & carcinogenesisCancer researchFemalebusinessmast cell estrogen receptor breast cancer luminal phenotypeEstrogen receptor alpha
researchProduct

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled ana…

2021

Few studies have explored the association between baseline characteristics and the occurrence of early toxicities in patients treated with first-line chemotherapy for metastatic colorectal cancer (mCRC).Individual patient data of 2190 patients enrolled in 10 prospective FFCD (Fédération Francophone de Cancérologie Digestive) trials were analysed. Severe early toxicity was defined as the occurrence of grade ≥III toxicity within 3 months after initiation of chemotherapy (ET3).Patients received monotherapy based on 5-FU (n = 1068), a cytotoxic doublet (n = 395) or tritherapy with a cytotoxic doublet plus anti-VEGF agent or a cytotoxic triplet (n = 727). The patients received 5-FU (100%), Irino…

Male0301 basic medicineCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancermedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProspective StudiesNeoplasm MetastasisAgedAfliberceptChemotherapyPerformance statusbusiness.industryMiddle AgedPrognosismedicine.diseaseOxaliplatinIrinotecanTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisToxicityFemaleColorectal Neoplasmsbusinessmedicine.drugEuropean Journal of Cancer
researchProduct

Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA

2018

Background: Scant real-world data exist on the clinical outcomes associated with the use of bevacizumab-containing chemotherapy (B+CT) in patients with metastatic colorectal cancer (mCRC). The primary objective of the GRETA cohort study was to compare the overall survival (OS) of patients with mCRC treated with first-line B+CT versus chemotherapy (CT) alone, in an Italian clinical practice setting. Materials and Methods: Incident patients with mCRC were identified during the period 2010–2012 from five population-based cancer registries in Italy. Cases were linked to regional health care utilization databases to obtain the entire spectrum of health services provided to each patient. Patients…

Male0301 basic medicineCancer Researchmedicine.medical_specialtyBevacizumabPropensity scoreColorectal cancerHealth Outcomes and Economics of Cancer CarePopulationSettore MED/42 - Igiene Generale E ApplicataCohort StudiesColorectal neoplasm03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineSurvival analysiInternal medicineObservational studymedicineHumansNeoplasm MetastasiseducationAgededucation.field_of_studybusiness.industryHazard ratioCancerMiddle Agedmedicine.diseaseBevacizumab030104 developmental biologyOncology030220 oncology & carcinogenesisPropensity score matchingCohortFemaleColorectal Neoplasmsbusinessmedicine.drugCohort study
researchProduct

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract can…

2019

Background To date, the cornerstone of treatment in patients with advanced or metastatic cholangiocarcinoma (CCA) is systemic chemotherapy based on a combination of gemcitabine and a platinum derivative. Other therapeutic approaches including targeted agents and tyrosine kinase inhibitors (TKI) have demonstrated disappointing results, highlighting the complexity of CCA. Recently, drugs aiming at the inhibition of HER-receptors have shown first therapeutic benefit in patients with late stage disease. The aim of this phase I study was to test the dose level toxicities (DLTs), safety and efficacy of afatinib, a highly specific panErbB family receptor TKI, in chemotherapy naive patients with ad…

Male0301 basic medicineOncologyCancer ResearchAfatinibDeoxycytidineTranslational Research BiomedicalCholangiocarcinoma0302 clinical medicineSurgical oncologyAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Metastasismedia_commonAged 80 and overpanHER inhibitionMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmunohistochemistryErbB ReceptorsBiliary Tract NeoplasmsTreatment OutcomeOncology030220 oncology & carcinogenesisBiomarker (medicine)FemaleTyrosine kinaseSignal TransductionResearch Articlemedicine.drugAdultDrugmedicine.medical_specialtyBIBW 2992media_common.quotation_subjectEGFRAfatiniblcsh:RC254-28203 medical and health sciencesInternal medicineGeneticsmedicineHumansProgression-free survivalAgedNeoplasm StagingCisplatinbusiness.industryGemcitabineGemcitabine030104 developmental biologyCisplatinbusinessBiomarkersBMC Cancer
researchProduct

Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin

2016

BACKGROUND: High Neutrophil/Lymphocyte ratio (NLR), as a measure of enhanced inflammatory response, has been negatively associated with prognosis in patients with localized pancreatic ductal adenocarcinoma (PDA). OBJECTIVE: In the present study, we aimed at investigating the prognostic value of NLR in two homogeneous groups of chemotherapy-na've metastatic PDA patients. Patients were treated with either gemcitabine (GEM) or gemcitabine/ oxaliplatin (GEMOXA). We also assessed whether NLR could identify patients benefiting from the use of oxaliplatin. METHODS: Consecutive PDA patients treated at the Medical Oncology Unit of Tor Vergata University Hospital of Rome with either GEM or GEMOXA wer…

Male0301 basic medicineOncologyCancer ResearchNeutrophil/lymphocyte ratio; gemcitabine; oxaliplatin; pancreatic ductal adenocarcinomaOrganoplatinum CompoundsNeutrophilsSettore MED/06 - Oncologia MedicaLymphocyteAntineoplastic AgentLeukocyte Count0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsLymphocytesNeoplasm MetastasisAged 80 and overNeutrophilPancreatic NeoplasmgemcitabineGeneral MedicineMiddle AgedPrognosisNeoplasm MetastasiTreatment Outcomemedicine.anatomical_structureOncology030220 oncology & carcinogenesisNeutrophil/lymphocyte ratioLymphocyteFemaleHumanCarcinoma Pancreatic Ductalmedicine.drugAdultmedicine.medical_specialtyPancreatic ductal adenocarcinomaPrognosiInflammatory responseeducationpancreatic ductal adenocarcinomaAntineoplastic Agents03 medical and health sciencesGeneticNegatively associatedInternal medicineMetastatic pancreatic cancerGeneticsmedicineHumansIn patientAgedProportional Hazards ModelsSettore MED/04 - Patologia GeneraleAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundfungioxaliplatinBiomarkerGemcitabineOxaliplatinPancreatic Neoplasms030104 developmental biologyROC CurveProportional Hazards ModelbusinessBiomarkers
researchProduct

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort…

2021

BackgroundCheckpoint inhibitors revolutionized the treatment of metastatic melanoma patients. Although tumor burden and lactate dehydrogenase (LDH) are associated with overall survival (OS), the impact of tumor growth kinetics remains elusive and in part contradictory. The aims of this study were to develop a novel simple and rapid method that estimates pretreatment metastatic growth rate (MGR) and to investigate its prognostic impact in melanoma patients treated with antiprogrammed death receptor-1 (PD-1) antibodies.MethodsMGR was assessed in three independent cohorts of a total of 337 unselected consecutive metastasized stage IIIB–IV melanoma patients (discovery cohort: n=53, confirmation…

Male0301 basic medicineOncologyCancer ResearchSkin NeoplasmsTime Factors2437Programmed Cell Death 1 ReceptorPembrolizumabMetastasis0302 clinical medicineRisk FactorsImmunotherapy BiomarkersImmunology and Allergy1506Immune Checkpoint InhibitorsRC254-282MelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle Agedddc:EuropeNivolumabTreatment OutcomeOncology030220 oncology & carcinogenesisCohortMolecular MedicineFemaleimmunotherapyNivolumabCohort studytumormedicine.medical_specialtyImmunologyAntibodies Monoclonal HumanizedRisk Assessment03 medical and health sciencesPredictive Value of TestsInternal medicinemelanomamedicineHumansCell ProliferationNeoplasm StagingRetrospective StudiesPharmacologyProportional hazards modelbusiness.industrybiomarkersReproducibility of Resultsmedicine.disease030104 developmental biologyTomography X-Ray ComputedbusinessBrain metastasis
researchProduct

The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study

2017

Background/Aim: To evaluate the effectiveness of enzalutamide in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer, progressing after chemotherapy with docetaxel plus prednisone. Patients and Methods: A total of 60 patients were enrolled. Reduction in serum prostate-specific antigen (PSA) was assessed as the primary endpoint, while reduction in pain, safety, progression-free survival and overall survival represented secondary endpoints. Results: Enzalutamide was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum levels of PSA before and after treatment was observed. A significant …

Male0301 basic medicineOncologyCancer Researchmedicine.medical_treatmentDocetaxelKaplan-Meier Estimateurologic and male genital diseasesDrug resistantAntineoplastic Agentchemistry.chemical_compoundProstate cancer0302 clinical medicinePrednisoneClinical endpointProspective StudiesNeoplasm MetastasisProspective cohort studyAged 80 and overProstate cancerGeneral MedicineMiddle AgedNeoplasm MetastasiProstatic Neoplasms Castration-ResistantProstate-specific antigenTreatment OutcomeOncologyDocetaxel030220 oncology & carcinogenesisBenzamidesRegression AnalysisTaxoidsHumanmedicine.drugmedicine.medical_specialtyAntineoplastic AgentsAdenocarcinomaRegression Analysi03 medical and health sciencesTaxoidInternal medicineNitrilesPhenylthiohydantoinEnzalutamidemedicineChemotherapyHumansEnzalutamideAgedChemotherapybusiness.industryProstatic NeoplasmsProstate-Specific Antigenmedicine.diseaseProspective Studie030104 developmental biologychemistryDrug Resistance NeoplasmProstatic NeoplasmPrednisonebusinessAnticancer Research
researchProduct

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR…

2017

BACKGROUND: There is increasing evidence that metastatic colorectal cancer (mCRC) is a genetically heterogeneous disease and that tumours arising from different sides of the colon (left versus right) have different clinical outcomes. Furthermore, previous analyses comparing the activity of different classes of targeted agents in patients with KRAS wild-type (wt) or RAS wt mCRC suggest that primary tumour location (side), might be both prognostic and predictive for clinical outcome. METHODS: This retrospective analysis investigated the prognostic and predictive influence of the localization of the primary tumour in patients with unresectable RAS wt mCRC included in six randomized trials (CRY…

Male0301 basic medicineOncologyColorectal cancermedicine.medical_treatmentCetuximabmedicine.disease_causeEGFR Antibody0302 clinical medicineAntineoplastic Agents ImmunologicalNeoplasias ColorrectaisMedicineNeoplasm MetastasisRandomized Controlled Trials as Topicpredictive valuePanitumumabHazard ratiotumour sideAntibodies MonoclonalHematologyPrognosisChemotherapy regimenErbB ReceptorsBevacizumabTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleKRASColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyBevacizumabcolorectal cancerGenes ras03 medical and health sciencesAnticorpos MonoclonaisInternal medicineHumansChemotherapybusiness.industryAntineoplásicos ImunológicosOdds ratiomedicine.diseaserandomised trial030104 developmental biologyGenes rasHuman medicinebusinessprognosticanti-EGFR treatment
researchProduct